glycoside/inflammation

FIELD OF THE INVENTION The present invention relates to pharmaceutical compositions containing certain flavonoid glycoside-type compounds that have been shown in the present invention to be therapeutically useful, and in particular have been shown to be useful as analgesics and anti-inflammatory for

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is directed to methods for reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the time dependent administration of an oligosaccharide glycoside related to

FIELD OF THE INVENTION This invention relates to the use of glycosides of mono- or diacylglycerol, e.g. 3-.beta.-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propany- l octadeca-9Z,12Z,15Z-trienoate (a constituent of rose-hips (the fruits of Rosa canina L.)), for the treatment of

FIELD OF THE INVENTION The invention relates to the field of medicinal chemistry, and more specifically to steroidal glycosides wherein the glycoside is linked directly, or indirectly to a desired steroidal compound via a carbon linkage, to formulations containing such, and their use in treating

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to glycosides, the salts thereof and pharmaceutical compositions containing these glycosides as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to glycosides, the salts thereof and pharmaceutical compositions containing these glycosides as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of

The present invention relates, e.g., to compositions and pharmaceutical compositions for the treatment and/or prevention of osteoporosis and/or inflammatory joint diseases, methods of treating and/or preventing osteoporosis and/or inflammatory joint diseases and the use of the aforementioned

BACKGROUND OF THE INVENTION The invention is generally related to the treatment of inflammatory conditions. More specifically, the invention is related to compositions containing inhibitors of mast cell activation and secretion such as a proteoglycan and a flavonoid compound that are designed to be

TECHNICAL FIELD The present invention relates to a novel agent or composition for use as a muscle-strengthening drug, an anti-inflammatory drug, an antiasthmatic, an antidiarrheal, an antidepressant, or a drug for the treatment of secondary diseases following cerebral infarction (human stroke

BACKGROUND OF THE INVENTION The present invention relates to novel anti-inflammatory compounds useful in the treatment of gastrointestinal inflammation. The invention further relates to a method of controlling the delivery of anti-inflammatory compounds, particularly mesalamine (5-amino salicylic

FIELD OF THE INVENTION This invention relates to spiroketalins (3B-hydroxy-5-ene- or 3B-hydroxy -5.alpha.-spiroketalsteroid 3-mono- and 3-disaccharides) as well as their monocarboxylic and dicarboxylic acid derived esters as well as their hemiesters, and their application in the treatment of human

FIELD OF THE INVENTION This invention relates generally to medicinal chemistry, and preferably to methods of synthesizing and identifying medically useful glyco-amino acids or glycopeptides which are characterized by their capacity to bind to one or more selectins CE-, L-, and

BACKGROUND OF THE INVENTION In one aspect, the invention relates to an antioxidant derived from lentil seed husks. In another aspect, the invention relates to a process for preparing the antioxidant. In yet another aspect, the invention relates to uses for the antioxidant. Plant seed coats sometimes

TECHNICAL FIELD The invention relates to agents that inhibit the activation of Factor X, and thus are candidates for treatment or prevention of thrombosis. More specifically, the invention concerns agents that affect the normal glycosylation pattern of Factor X and thus diminish its conversion to

TECHNICAL FIELD The invention relates to agents that inhibit the activation of Factor X, and thus are candidates for treatment or prevention of thrombosis. More specifically, the invention concerns agents that affect the normal glycosylation pattern of Factor X and thus diminish its conversion to